Publications by authors named "M H Deininger"
Starting with imatinib, tyrosine kinase inhibitors (TKIs) have turned chronic myeloid leukemia (CML) from a lethal blood cancer into a chronic condition. As patients with access to advanced CML care have an almost normal life expectancy, there is a perception that CML is a problem of the past, and one should direct research resources elsewhere. However, a closer look at the current CML landscape reveals a more nuanced picture.
View Article and Find Full Text PDFA small number of patients with chronic myeloid leukemia (CML) either present with or progress to the accelerated phase (AP) or blast phase (BP). This occurs in approximately 4-7% of patients with CML. Most patients who progress to BP-CML are of myeloid lineage, while approximately 30% are of lymphoid lineage.
View Article and Find Full Text PDFArticle Synopsis
- Lysine acylation influences how proteins function, where they go within the cell, and how they interact with other molecules, while sirtuins help regulate this process to maintain cellular balance, with their dysregulation linked to diseases like cancer.
- The accurate measurement of sirtuin activity is crucial for understanding their therapeutic potential but is currently challenging, leading to the development of a new assay called "SIRTify."
- SIRTify utilizes a sophisticated luciferase system to measure sirtuin activity in a way that reflects their specific interactions with lysine acylations, potentially providing insights into other types of protein modifications as well.
Delayed cerebral ischemia (DCI) is a severe complication following aneurysmal subarachnoid hemorrhage (aSAH), linked to poor functional outcomes and prolonged intensive care unit (ICU) stays. Timely DCI diagnosis is crucial but remains challenging. Dysregulated blood glucose, commonly observed after aSAH, may impair the constant glucose supply that is vital for brain function, potentially contributing to DCI.
View Article and Find Full Text PDF